Value of Heart Rate Lowering Therapy in Acute Myocarditis
1 other identifier
observational
150
1 country
1
Brief Summary
To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 9, 2024
CompletedFirst Posted
Study publicly available on registry
March 15, 2024
CompletedStudy Start
First participant enrolled
April 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedMarch 15, 2024
March 1, 2024
1 year
March 9, 2024
March 9, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Value of Heart Rate Lowering Therapy in Acute Myocarditis
To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.
baseline
Study Arms (3)
Conventional anti-inflammatory treatment (control group).
Conventional ttt PLUS Carvedilol.
Conventional ttt PLUS Ivabradine.
Interventions
Eligibility Criteria
Patients who meet the study's inclusion \& exclusion criteria
You may qualify if:
- Adults: ≥18 years of age.
- Presentation: at least one of the following:
- Myopericarditis/ACS-like
- MINOCA
- Arrhythmias: brady or tachyarrhythmias.
- Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically).
- TTE: LVEF\>40%
- CMR-confirmed myo(peri)carditis (Lake Louise criteria)
You may not qualify if:
- Rheumatic carditis.
- Connective tissue diseases (-ve ANA).
- Cancer chemotherapy.
- Toxicity from immunotherapy.
- Vaccine-related myocarditis.
- Presence of coronary artery disease.
- Peripartum (occurring during the last month of pregnancy or within 5 months after delivery)
- ECG: atrial fibrillation/flutter.
- Resuscitated sudden death.
- Early/initial phase of decompensated heart failure.
- Tamponade complicating pericarditis unless successfully managed.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Heart Hospital
Asyut, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident at student hospital , assiut university
Study Record Dates
First Submitted
March 9, 2024
First Posted
March 15, 2024
Study Start
April 1, 2024
Primary Completion
April 1, 2025
Study Completion
June 1, 2025
Last Updated
March 15, 2024
Record last verified: 2024-03